Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
How to read a next-generation sequencing report-what oncologists need to know.
Schmid S, Jochum W, Padberg B, Demmer I, Mertz K, Joerger M, Britschgi C, Matter M, Rothschild S, Omlin A. How to read a next-generation sequencing report-what oncologists need to know. ESMO Open 2022; 7:100570.
29.09.2022How to read a next-generation sequencing report-what oncologists need to know.
29.09.2022ESMO Open 2022; 7:100570
Schmid S, Jochum W, Padberg Barbara, Demmer I, Mertz K D, Joerger M, Britschgi C, Matter M, Rothschild S I, Omlin Aurelius
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. Eur J Cancer 2022; 175:224-235.
22.09.2022Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
22.09.2022Eur J Cancer 2022; 175:224-235
Müller-Jensen Leonie, Zierold Sarah, Versluis Judith M, Boehmerle Wolfgang, Huehnchen Petra, Endres Matthias, Mohr Raphael, Compter Annette, Blank Christian U, Hagenacker Tim, Meier Friedegund, Reinhardt Lydia, Gesierich Anja, Salzmann Martin, Hassel Jessica C, Ugurel Selma, Zimmer Lisa, Banks Patricia, Spain Lavinia, Soon Jennifer A, Enokida Tomohiro, Tahara Makoto, Kähler Katharina C, Seggewiss-Bernhardt Ruth, Harvey Catriona, Long Georgina V, Schöberl Florian, von Baumgarten Louisa, Hundsberger Thomas, Schlaak Max, French Lars E, Knauss Samuel, Heinzerling Lucie M
Call for a holistic framework for cancer immunotherapy.
Boesch M, Baty F, Kowatsch T, Wolf D, Früh M, Brutsche M. Call for a holistic framework for cancer immunotherapy. Cancer 2022; 128:3772-3774.
15.09.2022Call for a holistic framework for cancer immunotherapy.
15.09.2022Cancer 2022; 128:3772-3774
Boesch Maximilian, Baty Florent, Kowatsch Tobias, Wolf Dominik, Früh Martin, Brutsche Martin H
Decision-making among experts in advanced Hodgkin Lymphoma.
Hitz F, Lang N, Mey U, Mingrone W, Moccia A, Taverna C, Novak U, Stenner F, Schmidt A, Mamot C, Fischer N, Putora P. Decision-making among experts in advanced Hodgkin Lymphoma. Oncology 2022
14.09.2022Decision-making among experts in advanced Hodgkin Lymphoma.
14.09.2022Oncology 2022
Hitz Felicitas, Lang Noémie, Mey Ulrich, Mingrone Walter, Moccia Alden, Taverna Christian, Novak Urban, Stenner Frank, Schmidt Adrian, Mamot Christoph, Fischer Natalie, Putora Paul Martin
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
02.09.2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
02.09.2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
Jakeman B, Scherrer A, Darling K, Damas J, Bieler-Aeschlimann M, Hasse B, Schlosser L, Hachfeld A, Gutbrod K, Tarr P, Calmy A, Assal F, Kunze U, Stoeckle M, Schmid P, Rossi S, Di Benedetto C, Du Pasquier R, Cavassini M, Marzolini C, Hundsberger T. Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus. Open Forum Infect Dis 2022; 9:ofac457.
02.09.2022Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
02.09.2022Open Forum Infect Dis 2022; 9:ofac457
Jakeman Bernadette, Scherrer Alexandra U, Darling Katharine E A, Damas José, Bieler-Aeschlimann Melanie, Hasse Barbara, Schlosser Ladina, Hachfeld Anna, Gutbrod Klemens, Tarr Philip E, Calmy Alexandra, Assal Frédéric, Kunze Ursula, Stoeckle Marcel, Schmid Patrick, Rossi Stefania, Di Benedetto Caroline, Du Pasquier Renaud, Cavassini Matthias, Marzolini Catia, Hundsberger Thomas
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Adamina M, Warlaumont M, Berger M, Däster S, Delaloye R, Digklia A, Gloor B, Fritsch R, Koeberle D, Koessler T, Lehmann K, Müller P, Peterli R, Ris F, Steffen T, Weisshaupt C, Hübner M. Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. Cancers (Basel) 2022; 14
01.09.2022Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
01.09.2022Cancers (Basel) 2022; 14
Adamina Michel, Warlaumont Maxime, Berger Martin D, Däster Silvio, Delaloye Raphaël, Digklia Antonia, Gloor Beat, Fritsch Ralph, Koeberle Dieter, Koessler Thibaud, Lehmann Kuno, Müller Phaedra, Peterli Ralph, Ris Frédéric, Steffen Thomas, Weisshaupt Christian, Hübner Martin
Patient satisfaction with divided anesthesia care.
Koster K, Björklund C, Fenner S, Flierler W, Laupheimer M, Burri K, Nübling M, Heidegger T. Patient satisfaction with divided anesthesia care. Anaesthesiologie 2022
29.08.2022Patient satisfaction with divided anesthesia care.
29.08.2022Anaesthesiologie 2022
Koster Kira-Lee, Björklund Carolin, Fenner Sebastian, Flierler Wolfgang Johann, Laupheimer Michael, Burri Katharina, Nübling Matthias, Heidegger Thomas
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer 2022; 172:154-159.
28.08.2022Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
28.08.2022Lung Cancer 2022; 172:154-159
Addeo Alfredo, Rothschild Sacha I, Holer Lisa, Schneider Martina, Waibel Christine, Haefliger Simon, Mark Michael, Fernandez Eugenio, Mach Nicolas, Mauti Laetitia, Jermann Philip, Alborelli Ilaria, Calgua Byron, Savic-Prince Spasenija, Joerger Markus, Früh Martin
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case Rep Oncol 2022; 15:720-725.
26.08.2022Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
26.08.2022Case Rep Oncol 2022; 15:720-725
Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E, Fischer K, R Demmer-Steingruber, Nigg S, Güsewell S, Albrich W, Rothermundt C, Silzle T, Kahlert C. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment. ESMO Open 2022; 7:100587.
24.08.2022Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
24.08.2022ESMO Open 2022; 7:100587
Su E, Fischer Katharina S, R Demmer-Steingruber, Nigg Susanne, Güsewell Sabine, Albrich Werner, Rothermundt Christian, Silzle Tobias, Kahlert Christian
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, Furlanetto J, Zahm D, Hanusch C, GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022
09.08.2022Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
09.08.2022Ann Oncol 2022
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P A, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober Jens, Braun M, Rey J, Blohmer J-U, Furlanetto J, Zahm D-M, Hanusch C, GBG and AGO-B
A High-Energy Density Li-Ion Hybrid Capacitor Fabricated from Bio-Waste Derived Carbon Nanosheets Cathode and Graphite Anode.
Nanaji K, Pappu S, Anandan S, Rao T. A High-Energy Density Li-Ion Hybrid Capacitor Fabricated from Bio-Waste Derived Carbon Nanosheets Cathode and Graphite Anode. Glob Chall 2022; 6:2200082.
09.08.2022A High-Energy Density Li-Ion Hybrid Capacitor Fabricated from Bio-Waste Derived Carbon Nanosheets Cathode and Graphite Anode.
09.08.2022Glob Chall 2022; 6:2200082
Nanaji Katchala, Pappu Samhita, Anandan Srinivasan, Rao Tata Nageswara
Forgiveness and Reconciliation
Renz M. Forgiveness and Reconciliation - Initiating Individuation and Enabling Liberation. Routledge, Taylor & Francis Ltd, 2022. ISBN 9781032316970.
26.07.2022Forgiveness and Reconciliation
26.07.2022Routledge, Taylor & Francis Ltd, ISBN 9781032316970
Renz Monika
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
23.07.2022Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
23.07.2022Br J Clin Pharmacol 2022; 88:5336-5347
Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen J, Löwenberg B, Manz M, Biemond B, Westerweel P, Klein S, Fehr M, Sinnige H, Efthymiou A, Legdeur M, Pabst T, Gregor M, van der Poel M, Deeren D, Tick L, Jongen-Lavrencic M, van Obbergh F, Boersma R, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele G. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia 2022; 36:2189-2195.
22.07.2022Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
22.07.2022Leukemia 2022; 36:2189-2195
Janssen J J W M, Löwenberg Bob, Manz M, Biemond B J, Westerweel P E, Klein S K, Fehr M, Sinnige H A M, Efthymiou Anna, Legdeur M C J C, Pabst T, Gregor M, van der Poel M W M, Deeren Dries, Tick L W, Jongen-Lavrencic Mojca, van Obbergh F, Boersma R S, de Weerdt Okke, Chalandon Yves, Heim D, Spertini Olivier, van Sluis G, Graux Carlos, Stüssi G, van Norden Y, Ossenkoppele G J
Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice.
Rovó A, Baierlein-Leimbach C, Medri C, Chanias I, Errass L, Fehr T, Triemer T, McCarthy-Pontier D, Lehmann T. Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice. J Clin Med 2022; 11
21.07.2022Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice.
21.07.2022J Clin Med 2022; 11
Rovó Alicia, Baierlein-Leimbach Claudia, Medri Cesare, Chanias Ioannis, Errass Loreen, Fehr Theresa, Triemer Therese, McCarthy-Pontier Daphne B, Lehmann Thomas
Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson I, Lin Y, Lam C, Shao H, Tharp K, Hale M, Kasap C, Mariano M, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara S, Hann B, Driessen C, Van Ness B, Gestwicki J, Wiita A. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol 2022; 29:1288-1302.e7.
18.07.2022Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
18.07.2022Cell Chem Biol 2022; 29:1288-1302.e7
Ferguson Ian D, Lin Yu-Hsiu T, Lam Christine, Shao Hao, Tharp Kevin M, Hale Martina, Kasap Corynn, Mariano Margarette C, Kishishita Audrey, Patiño Escobar Bonell, Mandal Kamal, Steri Veronica, Wang Donghui, Phojanakong Paul, Tuomivaara Sami T, Hann Byron, Driessen Christoph, Van Ness Brian, Gestwicki Jason E, Wiita Arun P
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson I, Patiño-Escobar B, Tuomivaara S, Lin Y, Nix M, Leung K, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong S, Wolf J, Martin T, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey A, Mullins R, Eyquem J, Wells J, Wiita A. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun 2022; 13:4121.
15.07.2022The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
15.07.2022Nat Commun 2022; 13:4121
Ferguson Ian D, Patiño-Escobar Bonell, Tuomivaara Sami T, Lin Yu-Hsiu T, Nix Matthew A, Leung Kevin K, Kasap Corynn, Ramos Emilio, Nieves Vasquez Wilson, Talbot Alexis, Hale Martina, Naik Akul, Kishishita Audrey, Choudhry Priya, Lopez-Girona Antonia, Miao Weili, Wong Sandy W, Wolf Jeffrey L, Martin Thomas G, Shah Nina, Vandenberg Scott, Prakash Sonam, Besse Lenka, Driessen Christoph, Posey Avery D, Mullins R Dyche, Eyquem Justin, Wells James A, Wiita Arun P
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
12.07.2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
12.07.2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang